Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | HRH1 | P35367 | 3/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.31 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.31 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814443 | 0.91 | RXFP1 (0.35) | OGAACHEHRH1HRH4MRGPRX1 | |
| SCHEMBL2811035 | 0.89 | ACHE (0.37) | OGAACHEHRH1HRH4MRGPRX1 | |
| SCHEMBL2814269 | 0.85 | RXFP1 (0.36) | ACHEMRGPRX1MEN1KMT2AALDH1A1 | |
| SCHEMBL2816455 | 0.84 | SIGMAR1 (0.34) | OGAMRGPRX1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2813048 | 0.84 | IP6K1 (0.40) | KDM1AEHMT2RCOR1MEN1KMT2A | |
| SCHEMBL2816668 | 0.83 | MRGPRX1 (0.39) | OGAACHEHRH1HRH4MRGPRX1 | |
| SCHEMBL2809480 | 0.83 | SSTR5 (0.37) | ACHESMN1; SMN2 | |
| SCHEMBL2812918 | 0.82 | MRGPRX1 (0.38) | ACHEMRGPRX1ALDH1A1BACE1 | |
| SCHEMBL2810531 | 0.82 | MRGPRX1 (0.48) | OGAMRGPRX1MEN1KMT2A | |
| SCHEMBL2808425 | 0.82 | MRGPRX1 (0.39) | OGAHRH1HRH4MRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343983-B2 | Substituted pyrazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249110-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS | DPYD, TYMP, TP53 | OGA 3938/4885ACHE 4402/4885HRH1 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.